The International Journal of Cardiovascular Imaging

, Volume 28, Issue 2, pp 295–301

Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine


    • Department of Radiology, Mallinckrodt Institute of RadiologyWashington University School of Medicine
  • Thomas L. Chenevert
    • Department of RadiologyUniversity of Michigan
  • H. Dirk Sostman
    • Office of the Dean and Department of RadiologyWeill Cornell Medical College and Methodist Hospital
  • Kathleen A. Jablonski
    • The Biostatistics CenterGeorge Washington University
  • Paul D. Stein
    • Department of Internal Medicine, College of Osteopathic MedicineMichigan State University
  • Lawrence R. Goodman
    • Department of RadiologyMedical College of Wisconsin
  • Frank J. Londy
    • Department of RadiologyUniversity of Michigan
  • Vamsidhar Narra
    • Department of Radiology, Mallinckrodt Institute of RadiologyWashington University School of Medicine
  • Charles A. Hales
    • Department of MedicineMassachusetts General Hospital and Harvard Medical School
  • Russell D. Hull
    • Department of MedicineUniversity of Calgary
  • Victor F. Tapson
    • Department of MedicineDuke University
  • John G. Weg
    • Department of RadiologyUniversity of Michigan
Original Paper

DOI: 10.1007/s10554-011-9821-6

Cite this article as:
Woodard, P.K., Chenevert, T.L., Dirk Sostman, H. et al. Int J Cardiovasc Imaging (2012) 28: 295. doi:10.1007/s10554-011-9821-6


During a recent multi-center trial assessing gadolinium (Gd)-enhanced magnetic resonance angiography (MRA) for diagnosis of acute pulmonary embolism (PE), the Food and Drug Administration announced a risk of nephrogenic sclerosing fibrosis in patients with renal insufficiency who had received intravenous Gd-based MR contrast agents. Although no patients in this trial had renal insufficiency, in cautious response to this announcement, the trial protocol was changed from an intravenous administration of 0.2 mmol/Kg of a conventional Gd-based MR contrast agent to 0.1 mmol/Kg of gadobenate dimeglumine. The study described herein compares the signal quality of pulmonary MRA performed with double dose conventional agent to single dose gadobenate dimeglumine. This study is a retrospective analysis of data from a prospective, multicenter study in men and women ≥18 years with documented presence or absence of PE. The study was approved by the Institutional Review Board at all participating centers, and all patients provided written indication of informed consent. We performed both objective and subjective analysis of pulmonary artery image quality. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in the main pulmonary artery were assessed in single and double dose protocols and compared. SNR and CNR of the main PA were correlated with subjective quality assessment of main/lobar, segmental and subsegmental pulmonary arteries. Although there were individual outliers, both SNR (P = 0.01) and CNR (P = 0.008) were higher in all quartiles for examinations using gadobenate dimeglumine than with gadopentetate dimeglumine. Subjective quality of vascular signal intensity at each vessel order was significantly better for gadobenate dimeglumine (P < 0.0001), and correlated well with SNR and CNR at each order (<0.001). Because of agent high relaxivity, a single dose of gadobenate dimeglumine provides better pulmonary MRA signal quality than double dose of a conventional Gd-based MR contrast agent.


Pulmonary MR angiographyContrast agentsImage qualityPulmonary embolism

Copyright information

© Springer Science+Business Media, B.V. 2011